Effects of tamoxifen on spinal bone density in women with breast cancer.
Effects of tamoxifen on spinal bone density in women with breast cancer.
复制标题
他莫昔芬对乳腺癌女性脊柱骨密度的影响。
DOI：
10.1093/jnci/81.14.1086
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Lindsay,R
中科院分区：
文献类型：
--
作者：
Turken,S;Siris,E;Seldin,D;Flaster,E;Hyman,G;Lindsay,R
对10例绝经后乳腺癌患者在他莫昔芬治疗0、6、12个月后进行骨密度测定(L2-L4)，并与10例正常对照进行比较。患者和对照组在6个月(P<；.05)和12(P<；.003)月时有显著差异。他莫昔芬组治疗6个月和12个月后骨密度无显著增加(分别为+0.024±0.014和+0.022±0.018 g/cm~2)，而对照组治疗后6个月平均骨量下降(−为0.012±0.018 g/cm~2)，12个月后骨密度下降(−为0.024±0.01g/cm~2)。这些初步数据表明，在治疗的第一年，他莫昔芬的使用与骨量的保存有关。[美国癌症杂志81：1086-1088,1989]
Bone densitometry (L2-L4) was performed on 10 postmenopausal women with breast cancer after 0, 6, and 12 months of tamoxifen treatment; the results were compared with data from 10 normal controls. The patients and controls differed significantly at 6 (P<.05) and 12 (P<.003) months. The tamoxifen group showed a nonsignificant mean gain in bone mineral density after 6 and 12 months of treatment (+0.024 ± 0.014 and +0.022 ± 0.018 g/cm2, respectively), whereas the controls showed a nonsignificant mean loss of bone mass at 6 months (−0.012 ± 0.018 g/cm2and a statistically significant loss of bone density after 12 months (−0.024 ± 0.01 g/cm2). These preliminary data suggest that tamoxifen use is associated with preservation of bone mass during the first year of treatment. [J Natl Cancer Inst 81: 1086–1088, 1989]